Fig. 9: β1-AR agonist treatment prevents upregulation of mLT in BMDC. | Nature Communications

Fig. 9: β1-AR agonist treatment prevents upregulation of mLT in BMDC.

From: Early-life-trauma triggers interferon-β resistance and neurodegeneration in a multiple sclerosis model via downregulated β1-adrenergic signaling

Fig. 9: β1-AR agonist treatment prevents upregulation of mLT in BMDC.

a Relative expression of Lta mRNA in BMDC treated with adrenergic agonists and/or LPS and Mtb in vitro (n = 3 per group). Vehicle or AR agonists (100 µM) were pretreated to BMDC for 18 h. Then LPS (1 µg/ml) or heat-killed Mtb (100 µg/ml) was treated for 3 h. b Representative western blot and quantification for TRAF3 in BMDC 18 h after vehicle or β1-AR agonist (100 µM). n = 5 replicates/group. Each dot represents averaged data per animal. Data are represented as mean ± SEM. Student’s t-test, *P < 0.05. Exact P values for asterisks (from left to right): a 0.0042, 0.0249; b 0.0415.

Back to article page